Stephens Inc. AR Buys 1,608 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Stephens Inc. AR significantly increased its stake in IDEXX Laboratories by 92.8% during the 2nd quarter, owning 3,340 shares valued at approximately $1.79 million after purchasing an additional 1,608 shares.
• IDEXX Laboratories reported impressive earnings, with a Q2 EPS of $3.63 surpassing analysts' estimates, and a revenue of $1.11 billion, up 10.6% compared to the previous year.
• Several institutional investors have made significant changes to their positions in IDEXX, with 87.84% of the company's stock now owned by institutional investors, showcasing strong institutional interest.

Stephens Inc. AR raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 92.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,340 shares of the company's stock after purchasing an additional 1,608 shares during the period. Stephens Inc. AR's holdings in IDEXX Laboratories were worth $1,791,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mutual of America Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 79.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company's stock valued at $8,160,000 after purchasing an additional 8,609 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 3,766.7% in the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock valued at $49,000 after acquiring an additional 113 shares during the last quarter. Plato Investment Management Ltd lifted its holdings in shares of IDEXX Laboratories by 37.1% in the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company's stock valued at $1,310,000 after acquiring an additional 835 shares during the last quarter. Genesis Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $215,000. Finally, ORG Wealth Partners LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $273,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $638.60 on Friday. The firm has a market cap of $51.09 billion, a PE ratio of 53.17, a price-to-earnings-growth ratio of 4.10 and a beta of 1.58. The firm's 50 day simple moving average is $638.60 and its 200-day simple moving average is $555.86. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 2,187 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company's stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a report on Friday, August 15th. Piper Sandler reaffirmed a "neutral" rating and issued a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Sunday, September 28th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Finally, UBS Group initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, October 1st. They issued a "neutral" rating and a $720.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.